Autonomix medical, inc. finalizes design review of first-ever intravascular nerve sensing catheter in key step toward u.s. clinical studies

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system continued progress toward submitting investigational device exemption (“ide”), and if approved, the commencement of u.s. clinical trials to support a de novo fda application the woodlands, tx, aug. 14, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has advanced its proprietary sensing catheter through a final design review in preparation for human clinical trials. previous versions had been used in animal models to demonstrate the ability to detect nerve signals.
AMIX Ratings Summary
AMIX Quant Ranking